James Sherblom - Jan 4, 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol
CMRA
Transactions as of
Jan 4, 2023
Transactions value $
$120,000
Form type
4
Date filed
1/6/2023, 03:15 PM
Previous filing
Feb 14, 2023
Next filing
Feb 16, 2023
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMRA Common Stock Award $99.7K +81.1K +21.85% $1.23 452K Jan 4, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Warrants (right to buy) Award $20.3K +81.1K $0.25 81.1K Jan 4, 2023 Common Stock 162K $1.23 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 81,081 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
F2 The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.